Pharmacotherapy of alopecia areata

Alopecia areata (AA) presents a significant challenge as an autoimmune disorder characterized by localized hair loss. Despite its prevalence and impact on quality of life, its etiology remains elusive, although autoimmune processes involving CD8 + T cells are implicated. Corticosteroids, particularly intralesional injections and topical formulations, are the mainstay of treatment, showing efficacy in mild to moderate cases. However, severe forms like alopecia universalis pose therapeutic challenges. Janus kinase (JAK) inhibitors, notably baricitinib, ritlecitinib, upadacitinib and tofacitinib, offer promising results in inducing hair regrowth. Methotrexate and cyclosporine also demonstrate efficacy, especially in combination therapies. Minoxidil provides additional benefits, whereas tacrolimus requires further investigation for AA treatment. Pharmacological interventions offer diverse approaches to managing AA, addressing its multifactorial etiology and varied clinical presentations. Understanding the mechanisms of action and comparative effectiveness of these treatments is crucial for optimizing therapeutic outcomes and enhancing the quality of life for individuals affected by AA. This review focuses on current pharmacological options for managing AA.